Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.

A highly significant improvement from baseline in health status was observed for all eight domains and scores of the SF‐36 in all active treatment groups at Week 12, compared with the placebo group ( P < 0.001 for ‘general health’ and ‘health transition score’; P < 0.0001 for all other domains and scores; Table 2 ).

also in 132,142 other papers